Company Performance - Medpace (MEDP) closed at $521.21, reflecting a +1.34% increase from the previous day, outperforming the S&P 500's decline of 0.63% [1] - Over the past month, Medpace shares have risen by 3.31%, surpassing the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - Medpace is set to release its earnings on October 22, 2025, with an expected EPS of $3.5, representing a 16.28% increase year-over-year [2] - The consensus estimate for revenue is $640.45 million, indicating a 20.09% growth compared to the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates project earnings of $14.03 per share and revenue of $2.46 billion, reflecting increases of +11.08% and +16.86% respectively from the previous year [3] Analyst Revisions - Recent changes to analyst estimates for Medpace indicate a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests potential stock price performance [4] Valuation Metrics - Medpace has a Forward P/E ratio of 36.65, which is a premium compared to the industry average Forward P/E of 17.34 [5] - The PEG ratio for Medpace is currently 3.23, compared to the average PEG ratio of 1.73 for the Medical Services industry [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [6][7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Medpace (MEDP) closed at $536.17, down 1.42% from the previous session, underperforming the S&P 500's gain of 0.06% [1] - Over the past month, Medpace shares have increased by 13.02%, outperforming the Medical sector's gain of 5.06% and the S&P 500's gain of 3.94% [1] Upcoming Earnings - Medpace is set to release its earnings report on October 22, 2025, with an expected EPS of $3.49, reflecting a 15.95% increase from the same quarter last year [2] - The Zacks Consensus Estimate projects revenue of $640.76 million, up 20.14% from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $13.99 per share, indicating a 10.77% increase, while revenue is projected at $2.46 billion, showing a 16.83% increase from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive changes reflecting analyst optimism [3][4] Zacks Rank and Valuation - Medpace currently holds a Zacks Rank of 3 (Hold), with the Zacks Rank system historically outperforming, particularly stocks rated 1 [5] - The Forward P/E ratio for Medpace is 38.88, significantly higher than the industry average of 17.12, and the PEG ratio stands at 3.42 compared to the industry average of 1.64 [6] Industry Overview - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 135, placing it in the bottom 46% of all industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]